BioSpace News Archive

Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that the Company has entered into an agreement with Pfizer for the supply of a proprietary high-performance enzyme used to manufacture a critical intermediate for nirmatrelvir, an active pharmaceutical ingredient (API) in PAXLOVID™.

10x Genomics, Inc., a life sciences leader focused on mastering biology to advance human health, announced that its preliminary revenue is expected to be approximately $114.5 million for the second quarter ended June 30, 2022.

July 14, 2022 20:30 UTC Labcorp, a leading global life sciences company, announced that its Board of Directors has declared a cash dividend of $0.72 per share of common stock.

Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the second quarter of 2022 before the market opens on Thursday, July 28, 2022.

The global surgical instruments market is expected to reach USD 38.13 Billion in 2030 and register a revenue CAGR of 8.0% during the forecast period, according to the latest report published by Reports and Data.

The latest market analysis report published by Reports and Data, titled ‘Global Ziprasidone Market – Forecast to 2030,’ thoroughly examines the Ziprasidone industry to provide essential data & information for the targeted readers.

ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2022 on Thursday, August 11, 2022, after the New York Stock Exchange closes.

Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), today announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1/2, first-in-human, clinical study of OTX-2002 for the treatment of hepatocellular carcinoma (HCC).

Aurinia Pharmaceuticals Inc., a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, announced the appointment of three seasoned leaders to the Aurinia executive team.

MedX Health Corp. is pleased to announce that it has closed on the First tranche, of $250,000, of the non-brokered Private Placement announced in its Press Release of June 30, 2022.